Lilly Oncology to Release New Pipeline Data at ASCO 2013

           Lilly Oncology to Release New Pipeline Data at ASCO 2013

Data from Pipeline Molecules Targeting Key Cancer Pathways to be Presented

PR Newswire

INDIANAPOLIS, May 14, 2013

INDIANAPOLIS, May 14, 2013 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY)
will present data from key molecules that make up its clinical oncology
pipeline during the 49^th Annual Meeting of the American Society of Clinical
Oncology (ASCO) held in Chicago, Ill. from May 31 – June 4, 2013. Lilly
Oncology's pipeline is one of the most robust in the industry, with more than
20 molecules in early- and late-stage development, targeting a variety of
difficult-to-treat cancers.

"This year's ASCO conference theme, 'Building Bridges to Conquer Cancer,' is
especially relevant as it is vital to work together to find clinical solutions
to assist in the well-being of patients," said Richard Gaynor, M.D. vice
president of product development and medical affairs for Lilly Oncology. "In
today's medical landscape, the entire oncology community needs to constantly
be looking for ways to build bridges—with each other, with academia, with
patients and with theregulatory bodies. These bridges supply us with the
communication and knowledge we need to advance the treatment of cancer."

Select studies, along with the times and locations of their data sessions, are
highlighted below.

CDK4/6 Inhibitor (LY2835219)

  oAbstract #2500: Oral Abstract Session: Sunday, June 2, 2013, 8:00 AM -
    11:00 AM

       oA first-in-human Phase 1 study of the CDK4/6 inhibitor, LY2835219,
         for patients with advanced cancer
       oAuthor/Speaker: Geoffrey Shapiro, M.D., Ph.D.
       oLocation: S406

MET Antibody (LY2875358)

  oAbstract #8093: General Poster Session: Saturday, June 1, 2013, 8:00 AM -
    11:45 AM

       oFirst-in-human dose escalation study of LY2875358 (LY), a bivalent
         MET antibody, as monotherapy and in combination with erlotinib (E) in
         patients with advanced cancer
       oAuthor/Speaker: Jonathan W. Goldman, M.D.
       oLocation: S Hall A2

TGF Beta (LY2157299)

  oAbstract #4118: General Poster Session: Sunday, June 2, 2013, 8:00 AM -
    11:45 AM

       oRandomized dose comparison Phase 2 study of the oral transforming
         growth factor-beta (TGF-b) receptor I kinase inhibitor LY2157299
         monohydrate (LY) in patients with advanced hepatocellular carcinoma
       oAuthor/Speaker: Sandrine J. Faivre, M.D., Ph.D.
       oLocation: S Hall A2


This press release contains forward-looking statements about the potential of
LY2835219, LY2875358 and LY2157299 as treatments for various cancers and
reflects Lilly's current beliefs. However, as with any pharmaceutical product,
there are substantial risks and uncertainties in the process of development
and commercialization. There is no guarantee that these products will be
commercially successful. For further discussion of these and other risks and
uncertainties, see Lilly's filings with the United States Securities and
Exchange Commission. Lilly undertakes no duty to update forward-looking

Media Inquiries:
Keri McGrath, Lilly Oncology          Neil Hochman, TogoRun
317-277-3768 (office)                 212-453-2067 (office)
317-370-8394 (mobile)                 516-784-9089 (mobile)
Email: Email:

(Logo: )

SOURCE Eli Lilly and Company
Press spacebar to pause and continue. Press esc to stop.